ACCESS Newswire

Strawberry Fields REIT LLC

Share
Strawberry Fields REIT Announces Acquisition of 4 Skilled Nursing Facilities for $19.25MM

SOUTH BEND, IN / ACCESSWIRE / September 3, 2024 / Strawberry Fields REIT, Inc. (NYSE AMERICAN:STRW) (the "Company") today announced, effective September 1st 2024, it completed two separate acquisitions for $19.25 million of four Skilled Nursing Facilities ("SNF") located in Tennessee and Texas.

The first acquisition for $15.25 million included:

  • 75 bed SNF located in Hondo, TX.

  • 179 bed SNF located in Kerrville, TX.

Both these facilities will be leased to the Tide Group led by its founder Brian Ramos. The lease is for an initial 10-year period and includes two 5-year tenant options on a triple-net basis. Additionally, the lease will increase the Company's annual rents by $1.525 million and is subject to 3% annual increases.

The second acquisition for $4 million included:

  • 67 bed SNF located in Kingsport, TN.

  • 181 bed SNF located in Maryville, TN.

This acquisition was associated with a lease purchase option that the Company entered into on January 1, 2024. The Kingsport facility was added to an existing Infinity of Tennessee Master Lease and the Maryville facility was leased to a third party tenant. Collectively these facilities increased the Company's annual rents by $400 thousand and are both subject to 3% annual increases.

Moishe Gubin, the Company's Chairman & CEO, noted: "I am happy to announce the acquisition of these facilities. Tennessee and Texas are both states we have previously expressed interest in growing in and the Company continues to look for opportunities of future growth. I am also excited to welcome Brian and his team to our Strawberry Fields REIT family; we look forward to them succeeding in these facilities and growing with them on future opportunities."

About Strawberry Fields REIT
Strawberry Fields REIT, Inc., is a self-administered real estate investment trust engaged in the ownership, acquisition, development and leasing of skilled nursing and certain other healthcare-related properties. The Company's portfolio includes 112 healthcare facilities with an aggregate of 12,700+ beds, located throughout the states of Arkansas, Illinois, Indiana, Kentucky, Michigan, Ohio, Oklahoma, Tennessee and Texas. The 112 healthcare facilities comprise 102 skilled nursing facilities, eight assisted living facilities, and two long-term acute care hospitals.

Safe Harbor Statement
Certain statements in this press release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Those forward-looking statements include all statements that are not historical statements of fact and those regarding our intent, belief or expectations, including, but not limited to, statements regarding: future financing plans, business strategies, growth prospects and operating and financial performance; expectations regarding the making of distributions and the payment of dividends; and compliance with and changes in governmental regulations.

Words such as "anticipate(s)," "expect(s)," "intend(s)," "plan(s)," "believe(s)," "may," "will," "would," "could," "should," "seek(s)" and similar expressions, or the negative of these terms, are intended to identify such forward-looking statements. These statements are based on management's current expectations and beliefs and are subject to a number of risks and uncertainties that could lead to actual results differing materially from those projected, forecasted or expected. Although we believe that the assumptions underlying the forward-looking statements are reasonable, we can give no assurance that our expectations will be attained. Factors which could have a material adverse effect on our operations and future prospects or which could cause actual results to differ materially from our expectations include, but are not limited to: (i) the COVID-19 pandemic and the measures taken to prevent its spread and the related impact on our business or the businesses of our tenants; (ii) the ability and willingness of our tenants to meet and/or perform their obligations under the triple-net leases we have entered into with them, including, without limitation, their respective obligations to indemnify, defend and hold us harmless from and against various claims, litigation and liabilities; (iii) the ability of our tenants to comply with applicable laws, rules and regulations in the operation of the properties we lease to them; (iv) the ability and willingness of our tenants to renew their leases with us upon their expiration, and the ability to reposition our properties on the same or better terms in the event of nonrenewal or in the event we replace an existing tenant, as well as any obligations, including indemnification obligations, we may incur in connection with the replacement of an existing tenant; (v) the availability of and the ability to identify (a) tenants who meet our credit and operating standards, and (b) suitable acquisition opportunities, and the ability to acquire and lease the respective properties to such tenants on favorable terms; (vi) the ability to generate sufficient cash flows to service our outstanding indebtedness; (vii) access to debt and equity capital markets; (viii) fluctuating interest rates; (ix) the ability to retain our key management personnel; (x) the ability to maintain our status as a real estate investment trust ("REIT"); (xi) changes in the U.S. tax law and other state, federal or local laws, whether or not specific to REITs; (xii) other risks inherent in the real estate business, including potential liability relating to environmental matters and illiquidity of real estate investments; and (xiii) any additional factors included under "Risk Factors" in our Annual Report Form 10-K dated March 19, 2024, including in the section entitled "Risk Factors" in Item 1A of Part I of such report, as such risk factors may be amended, supplemented or superseded from time to time by other reports we file with the SEC.

Forward-looking statements speak only as of the date of this press release. Except in the normal course of our public disclosure obligations, we expressly disclaim any obligation to release publicly any updates or revisions to any forward-looking statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any statement is based.

Investor Relations:
Strawberry Fields REIT, Inc.
IR@sfreit.com
+1 (773) 747-4100 x422

SOURCE: Strawberry Fields REIT LLC



View the original press release on accesswire.com

To view this piece of content from www.accesswire.com, please give your consent at the top of this page.

About ACCESS Newswire

DK

Subscribe to releases from ACCESS Newswire

Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from ACCESS Newswire

Datavault AI Announces Target to Expand its AI Driven Data Monetization Network to Over 100 Cities Across the Contiguous United States, Starting in the Second Half of 2026 with Corresponding 2027 Revenue Target12.1.2026 14:05:00 CET | Press release

Datavault AI expects to have a fully operational network with over 100 nodes across 33 cities nationwide, generating revenue in the second half of 2026. Target revenue for this project is $400 to $500 million, thereby supporting the $200 million revenue guidance for 2026. With the full deployment of Datavault AI's nodes across 100+ cities throughout the United States, the 2027 revenue target is $2.0 to $3.0 billion for 2027. New York and Philadelphia edge network activation positions Datavault AI to potentially capture a significant share of the insurance and financial sectors, the healthcare industry, and enterprise opportunities. PHILADELPHIA, PENNSYLVANIA / ACCESS Newswire / January 12, 2026 / Datavault AI Inc. (Nasdaq:DVLT), a leader in AI-driven data valuation, monetization, credentialing, and digital engagement technologies, today highlighted the strategic importance of its New York and Philadelphia edge network deployment with Available Infrastructure's SanQtum AI platform. This

OBI Pharma and TegMine Therapeutics Sign Exclusive Global License Agreement for Glycan-Targeting ADC12.1.2026 13:00:00 CET | Press release

Successful Delivery of Commissioned ADC Candidate to Advance the Collaboration Between OBI and TegMine TAIPEI, TW / ACCESS Newswire / January 12, 2026 / OBI Pharma (4174.TWO) announced that it has entered into a commercial license agreement with TegMine Therapeutics, Inc. (TegMine), a San Francisco-based biopharma focused on developing antibodies targeting cancer-associated glycans and glycoproteins, for a glycan-targeting ADC. Under the terms of the agreement, OBI is eligible to receive an upfront payment as well as development and commercial milestones. Following product launch, OBI will also receive royalties based on a tiered percentage of annual net sales. While the detailed financial terms are not disclosed in accordance with the confidentiality provisions, the overall deal economics are broadly comparable to those of recent similar licensing transactions in the market. TegMine will obtain the exclusive global rights to develop and commercialize the ADC under the license agreemen

Charlie's Holdings (OTCQB:CHUC) Signs Agreement with IKE Tech to Commercialize Transformational Age-Gated Vapes that Will Address FDA Concerns Related to Youth Access12.1.2026 12:00:00 CET | Press release

SBX Product Line Will Feature First-Ever AI-Powered Blockchain-Based Age-Gating System for Vape Products IKE's patented biometric BLE Bluetooth chip and blockchain-based app will enable Charlie's to ensure that underage individuals will not be able to activate or utilize the Company's age-gated products. The IKE Licensing Agreement provides CHUC with a first mover advantage in youth access prevention (one of the FDA's top priorities) and a three-year exclusivity period for age-gated nicotine analogue products. Charlie's will test market the IKE age-gating system this spring with the Company's popular SBX nicotine analogue product line; simultaneously, Charlie's intends to incorporate the revolutionary technology into its PACHA branded Electronic Nicotine Delivery Systems (ENDS). COSTA MESA, CA / ACCESS Newswire / January 12, 2026 / Charlie's Holdings, Inc. (OTCQB:CHUC) ("Charlie's" or the "Company"), an industry leader in the premium vapor products space, today reported that the Compan

Datavault AI Celebrates Successful Completion of Dream Bowl XIV, Pioneering Blockchain Innovation in Sports Entertainment12.1.2026 12:00:00 CET | Press release

On January 10, 2026, a few dozen of NFL Alumni Greats (click here for a list of participating athletes) live-autographed 100 Footballs (click here to view the autographed NFL Alumni Footballs) and 500 Jerseys (click here to view the autographed NFL Alumni Jerseys); Starting on February 1, 2026, these special, one-time, live-autographed memorabilia items are to be given away by lottery to eligible holders of Dream Bowl Meme Coin I tokens and, following their distribution date (currently set for February 21, 2026), Dream Bowl Meme Coin II tokens and will be tradable on the upcoming International NIL Exchange; $25,000 E-Sports Scholarships Raised by Sponsors were Given to Dream Bowl Madden and Team E-Sports Champions; and 70 Student Star Athletes Showcased their Talent to USFL, NFL and European League Scouts (click here to view the Special Dream Bowl XIV Participants' Jerseys). PHILADELPHIA, PENNSYLVANIA / ACCESS Newswire / January 12, 2026 / Datavault AI Inc. (NASDAQ:DVLT) ("Datavault AI

PromiCell, Inc. presents during JP Morgan's 2026 Healthcare Conference9.1.2026 18:35:00 CET | Press release

MIAMI, FL / ACCESS Newswire / January 9, 2026 / PromiCell, Inc. (the "Company"), a clinical-stage cellular immunotherapy company uniquely positioned to advance potentially curative cell therapies for cancer patients, today announced that the Company's Chief Medical Officer, John Lee, MD, Ph.D., will present interim results of the Company's lead asset PRO CAR - 201A, a STEAP1 directed CAR T cell that is currently in the clinic as a first-in-human phase 1 trial for the treatment of metastatic castration-resistant prostate cancer (mCRPC), at Biotech Showcase 2026 in San Francisco, California on Monday, January 12, 2025 at 11:15 am PST at the Franciscan D (Ballroom Level). About PromiCell, Inc. PromiCell, is a clinical-stage cellular immunotherapy company with product candidates representing highly differentiated and novel CAR T and TCR T platforms to be developed across separate solid and hematologic types of cancer. Our pipeline of innovative products includes STEAP 1 CAR T cells, HA-1 T

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye